RAPA-201 Therapy of Solid Tumors
NCT05144698
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The therapy of solid tumors has been revolutionized by immune therapy, in particular, approaches that activate immune T cells in a polyclonal manner through blockade of checkpoint pathways such as PD-1 by administration of monoclonal antibodies. In this study, the investigators will evaluate the adoptive transfer of RAPA-201 cells, which are checkpoint-deficient polyclonal T cells that represent an analogous yet distinct immune therapy treatment platform for solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Solid Tumor
- Small Cell and Non-small Cell Lung Cancer
- Head and Neck Cancer
- Squamous Cell Carcinoma of Oral Cavity
- Squamous Cell Carcinoma of Larynx
- Squamous Cell Carcinoma of Nasopharynx
- Squamous Cell Carcinoma of Other Specified Sites of Skin
- Malignant Melanoma
- Esophageal Squamous Cell Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Rapa Therapeutics LLC
- Last updated on ClinicalTrials.gov
- May 14, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New Jersey · 1
- Hackensack University Medical Center · Hackensack, NJ
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.